Patents by Inventor Christopher Powell-Jones

Christopher Powell-Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of thrombotic events
    Patent number: 5977056
    Abstract: A method for preventing the formation of platelet-rich clots or thrombus, and for deaggregating platelet-rich clots or thrombus, using hementin, a polypeptide derived from leech salivary glands. Hementin may be administered for this purpose in a pharmaceutically acceptable carrier or excipient, with or without additional anticoagulants such as hirudin, hirudin analogues, or an inhibitor of factor Xa.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: November 2, 1999
    Assignee: Biopharm (UK) Limited
    Inventors: Christopher Powell-Jones, Roy T. Sawyer, Asgar Electricwala, Anthony Atkinson
  • Anti-thrombins
    Patent number: 5472942
    Abstract: A polypeptide derived from leeches of the species Hirudinaria manillensis has the following amino acid sequence: ##STR1## wherein Xaa indicates any amino acid residue; D indicates Cys or Pro; E indicates Glu, Asp or His; F indicates Asp, Lys or Trp; or a pharmaceutically acceptable salt, derivative or bioprecursor thereof. The polypeptide, and fragments thereof, is a specific anti-thrombin useful as a medicament.
    Type: Grant
    Filed: July 10, 1991
    Date of Patent: December 5, 1995
    Assignee: Biopharm (UK) Limited
    Inventors: Roy Sawyer, Christopher Powell-Jones, Anthony Atkinson, Asgar Electricwala
  • Pharmaceutical formulation containing heparin and endo-beta-glucuronidase, useful for the treatment of thrombosis
    Patent number: 5279824
    Abstract: A method of treating thrombosis with a pharmaceutical formulation comprising an endo-beta-glucuronidase, preferably leech-derived, heparin and a pharmacologically acceptable diluent, carrier or excipient which does not prevent the interaction between the heparin and the endo-beta-glucuronidase is disclosed. The formulation, which is disclosed, can also comprise a clot-lytic agent such as tissue plasminogen activator. Endo-beta-glucuronidase, unlike other hyaluronidases, has been found not to be inhibited by heparin.
    Type: Grant
    Filed: November 9, 1992
    Date of Patent: January 18, 1994
    Assignee: Merck Patent GmbH
    Inventors: Roy T. Sawyer, Christopher Powell-Jones